title: [New drugs of treatment of patients with chronic hepatitis B].
abstract: There are five approved drugs for the treatment of chronic hepatitis B(lamivudine, adefovir dipivoxil [ADV], entecavir [ETV], as well as pegylated and standard interferon) in Japan. In this paper, the reported data of new four drugs(tenofovir disoproxil fumarate [TDF], telbivudine, emtricitabine [FTC], clevudine) were described. TDF demonstrated potent antiviral efficacy in naive patients. Moreover, TDF is efficacious in lamivudine- or ADV-refractory patients. TDF monotherapy and the combination of FTC and TDF had similar efficacy in patients with incomplete viral suppression after therapy with ADV; response was not influenced by the presence of baseline lamivudine- or ADV-associated mutations.
authors.affiliation: Department of Hepatology, Toranomon Hospital.
authors.forename: Fumitaka
authors.initials: F
authors.lastname: Suzuki
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000068679:Emtricitabine; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D009705:Nucleosides / Q000627:therapeutic use; D063065:Organophosphonates / Q000627:therapeutic use; D011744:Pyrimidinones / Q000627:therapeutic use; D000077712:Telbivudine; D000068698:Tenofovir; D013936:Thymidine / Q000031:analogs & derivatives
chemical_list: D000998:Antiviral Agents; D009705:Nucleosides; D063065:Organophosphonates; D011744:Pyrimidinones; D003841:Deoxycytidine; D000077712:Telbivudine; D001086:Arabinofuranosyluracil; D000068698:Tenofovir; D000068679:Emtricitabine; C034935:clevudine; D000225:Adenine; D013936:Thymidine